Total U.S. permanent implant procedures declined 7% year over year, while U.S. trial procedures decreased 14.2% year over year. During the fourth quarter of 2024, Nevro made significant ...

It has been about a month since the last earnings report for Nevro (NVRO). Shares have added about 0.9% in that time frame, outperforming the S&P 500. Will the recent positive trend continue ...

U.S. permanent implant procedures decreased by 7.0% compared ... an increase of $15.5 million from September 30, 2024. Nevro's full-year 2024 worldwide revenue was $408.5 million, a decrease ...

enabling technologies and future implant solutions. Furthermore, the company’s scale and operational discipline will help optimize Nevro’s financial performance, driving enhanced profitability ...

However, Nevro faced challenges with a wider-than-expected loss per share of $1.41, significantly missing the analyst prediction of a $0.78 loss per share. U.S. revenue saw a decline of 9.9% to $91.4 ...

According to GMED administration, the deal allows them to expand into new markets for future growth while gaining access to Nevro’s world-class, differentiated technologies that can provide ...

NEVRO ($NVRO) is expected to release its quarterly earnings data on Tuesday, March 4th after market close, per Finnhub. Analysts are expecting revenue of $104,594,880 ...